Labcorp Holdings Inc. - LH STOCK NEWS

Outcomes4Me and Labcorp will present findings from their joint biomarker awareness study at the 2024 San Antonio Breast Cancer Symposium. The research focused on HER2-low awareness in metastatic breast cancer patients. The study revealed that 41.9% of patients with known HER2 status were not well-aware of HER2-low classification, and 51.3% of HER2-negative patients didn't recall discussing HER2-low with their oncologists.

Through a digital education campaign including discussion guides and webinars, the initiative showed promising results: 60.9% of patients with unknown HER2 status felt likely to discuss testing with their oncologist after engaging with the educational content. The study demonstrates how digital patient education can effectively increase biomarker awareness and encourage patient-provider discussions about testing.

Labcorp (NYSE: LH) announced that Executive Vice President and CFO Glenn Eisenberg will retire, with Julia Wang appointed as the new CFO effective December 2, 2024. Eisenberg will remain as Special Advisor to the CEO through April 2025. During Eisenberg's 10-year tenure, Labcorp doubled its revenues, completed approximately 100 acquisitions worth $11 billion, and returned over $6 billion to shareholders through repurchases and dividends. Wang joins from BeiGene, where she served as CFO and was key in driving business transformations through growth acceleration and operational efficiency.

Praia Health has secured a strategic investment from Labcorp Venture Fund and announced a collaboration to enhance patient lab ordering experiences. The partnership will integrate Praia Health's technology with Labcorp's testing capabilities to streamline lab testing processes. Praia's platform will provide personalized notifications within health systems' mobile apps, allowing patients to easily schedule lab tests and locate appropriate Labcorp facilities. The collaboration will initially launch at Providence's Puget Sound location, with plans to expand to other healthcare systems nationwide.

Labcorp (NYSE: LH) reported strong Q3 2024 results with revenue increasing 7.4% to $3.28 billion from $3.06 billion last year. Adjusted EPS rose to $3.50 from $3.38, while diluted EPS decreased to $2.00 from $2.11. The company updated its full-year 2024 guidance with revenue growth of 6.6% to 7.3% and adjusted EPS range of $14.30 to $14.70. During the quarter, Labcorp announced three new acquisitions/lab management agreements and completed two acquisitions, including select assets of BioReference Health and Invitae. Free cash flow was $162 million, down from $171 million in the previous year.

NOWDiagnostics (NOWDx) has announced a collaboration with Labcorp to distribute its First To Know® Syphilis Test in professional and healthcare settings across the U.S. This FDA-authorized over-the-counter test provides results in 15 minutes using a drop of blood. Labcorp plans to offer the test to professionals and hospitals by the end of 2024 and directly to patients through Labcorp OnDemand in 2025.

The collaboration aims to address the 80% increase in syphilis cases since 2018, affecting over 207,000 people, including more than 3,700 newborns in 2022. The partnership will expand access to testing, supporting earlier detection and treatment. Labcorp will also be the U.S. distribution partner for NOWDx's ADEXUSDx® hCG test used in hospital settings.

Labcorp (NYSE: LH) has expanded its STI testing portfolio with the First to Know® Syphilis Test, the first FDA-authorized over-the-counter blood test for syphilis. As the exclusive distributor for NOWDiagnostics (NOWDx) in the U.S., Labcorp will offer this rapid test to healthcare providers nationwide by the end of 2024 and to patients through Labcorp OnDemand in 2025.

The test provides results in 15 minutes using a single drop of blood from a fingerstick. This expansion aims to combat the rising syphilis cases in the U.S., which have increased by 80% between 2018 and 2022, reaching over 207,000 reported cases in 2022. Labcorp's syphilis testing volume has more than doubled in the past decade, exceeding 5.5 million tests annually.

Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024. This announcement demonstrates Labcorp's commitment to returning value to its shareholders and reflects the company's financial stability.

Advantage Healthcare Holdings, a regional leader in Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, has appointed Dinak (Dino) Nair as its new Chief Executive Officer, effective September 1, 2024. Nair succeeds Ryan Tong and brings over 20 years of business experience, including more than a decade in healthcare leadership roles.

Nair's previous positions include Vice President, General Manager of the Health Systems Operating Division at Labcorp (NYSE: LH), Senior Vice President at Thrive Skilled Pediatric Care, and Vice President of Operations at AdaptHealth. He holds an MBA in Public Accounting from Saint John's University.

Timothy Bovard, Chairperson of Advantage's Board, expressed confidence in Nair's ability to lead the company's growth and improve patient outcomes through personalized care. Nair stated his excitement to join Advantage and collaborate with the team to drive improved patient outcomes and deliver value to customers and stakeholders.

Labcorp (NYSE: LH), a global leader in innovative laboratory services, has announced it will release its third quarter 2024 financial results on Thursday, October 24, 2024, before the market opens. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results.

Investors can access the earnings press release and financial information on the Labcorp Investor Relations website. The call will be webcast live, and participants can register for dial-in access. A replay of the webcast will be available approximately two hours after the event and will remain accessible until September 10, 2025.